Select Publications
Book Chapters
2023, 'The role of nutrition in inflammatory bowel disease: Disease associations, management of active disease and maintenance of remission', in Encyclopedia of Human Nutrition: Volume 1-4, Fourth Edition, pp. 669 - 697, http://dx.doi.org/10.1016/B978-0-12-821848-8.00104-9
,Journal articles
2024, 'Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: A Randomized Controlled Trial', Clinical Gastroenterology and Hepatology, 22, pp. 2299 - 2308.e5, http://dx.doi.org/10.1016/j.cgh.2024.04.019
,2024, 'Dietary Determinants of Metabolic and Gut Microbial Health in Patients with Inflammatory Bowel Disease', Nutrients, 16, http://dx.doi.org/10.3390/nu16193233
,2024, 'Dietary Emulsifier Exposure in People with Inflammatory Bowel Disease Compared with Healthy Controls: Is There a Cause for Concern?', Inflammatory Bowel Diseases, 30, pp. 1241 - 1250, http://dx.doi.org/10.1093/ibd/izad318
,2024, 'P1005 Dose escalated Infliximab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program', Journal of Crohn's and Colitis, 18, pp. i1818 - i1818, http://dx.doi.org/10.1093/ecco-jcc/jjad212.1135
,2024, 'P1012 Dose escalated Ustekinumab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program', Journal of Crohn's and Colitis, 18, pp. i1829 - i1829, http://dx.doi.org/10.1093/ecco-jcc/jjad212.1142
,2024, 'P1030 Inflammatory Bowel Disease helpline contact trends in a real-world Australasian cohort: Crohn’s Colitis Cure (CCC) data insight’s program', Journal of Crohn's and Colitis, 18, pp. i1858 - i1859, http://dx.doi.org/10.1093/ecco-jcc/jjad212.1160
,2024, 'P1129 Fistulising Crohn's Disease in a large Australasian cohort - Crohn's Colitis Cure (CCC) Data Insights Program', Journal of Crohn's and Colitis, 18, pp. i2023 - i2023, http://dx.doi.org/10.1093/ecco-jcc/jjad212.1259
,2024, 'P1233 Serum insulin is associated with c-reactive protein and gut microbial diversity in inflammatory bowel disease', Journal of Crohn's and Colitis, 18, pp. i2183 - i2183, http://dx.doi.org/10.1093/ecco-jcc/jjad212.1363
,2024, 'P286 Variation of outcomes in inflammatory bowel disease at ten Australasian centres - Crohn's Colitis Cure (CCC) Data Insights Program', Journal of Crohn's and Colitis, 18, pp. i657 - i657, http://dx.doi.org/10.1093/ecco-jcc/jjad212.0416
,2024, 'P462 The burden of mental health disease in people with inflammatory bowel disease - Crohn's Colitis Cure (CCC) Data Insights Program', Journal of Crohn's and Colitis, 18, pp. i930 - i930, http://dx.doi.org/10.1093/ecco-jcc/jjad212.0592
,2024, 'P880 The real-world use of five-aminosalicylate (5ASA) treatment for Ulcerative Colitis in Australia and New Zealand: Crohn’s Colitis Cure (CCC) data insight’s program', Journal of Crohn's and Colitis, 18, pp. i1622 - i1623, http://dx.doi.org/10.1093/ecco-jcc/jjad212.1010
,2024, 'P959 Dose escalated vedolizumab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program', Journal of Crohn's and Colitis, 18, pp. i1742 - i1742, http://dx.doi.org/10.1093/ecco-jcc/jjad212.1089
,2024, 'High Technical Success Rate of Endoscopic Balloon Dilatation Reduces Surgical Requirement for Patients With Stricturing Crohn’s Disease', GastroHep, 2024, http://dx.doi.org/10.1155/2024/3686618
,2024, 'Mo1833 DOSE ESCALATED USTEKINUMAB IN INFLAMMATORY BOWEL DISEASE - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM', Gastroenterology, 166, http://dx.doi.org/10.1016/s0016-5085(24)03072-5
,2024, 'Mo1834 DOSE ESCALATED VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM', Gastroenterology, 166, pp. S - 1135, http://dx.doi.org/10.1016/s0016-5085(24)03073-7
,2024, 'Mo1835 DOSE ESCALATED INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM', Gastroenterology, 166, pp. S - 1135, http://dx.doi.org/10.1016/s0016-5085(24)03074-9
,2024, 'Su1841 VARIATION IN OUTCOMES IN INFLAMMATORY BOWEL DISEASE AT TEN AUSTRALASIAN CENTRES - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM', Gastroenterology, 166, pp. S - 839, http://dx.doi.org/10.1016/s0016-5085(24)02405-3
,2024, 'Su1874 THE BURDEN OF MENTAL HEALTH DISEASE IN PEOPLE WITH INFLAMMATORY BOWEL DISEASE - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM', Gastroenterology, 166, http://dx.doi.org/10.1016/s0016-5085(24)02438-7
,2024, 'Tu1891 THE REAL-WORLD USE OF FIVE-AMINOSALICYLATE (5ASA) TREATMENT FOR ULCERATIVE COLITIS IN AUSTRALIA AND NEW ZEALAND: CROHN'S COLITIS CURE (CCC) DATA INSIGHT'S PROGRAM', Gastroenterology, 166, http://dx.doi.org/10.1016/s0016-5085(24)03792-2
,2023, 'P413 Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial', Journal of Crohn's and Colitis, 17, pp. i542 - i543, http://dx.doi.org/10.1093/ecco-jcc/jjac190.0543
,2023, 'P523 Quality, safety and equity of care outcomes for inflammatory bowel disease patients at four tertiary referral centres in Australia using a cloud based management system Crohn’s Colitis Care (CCCare): A real world observational study.', Journal of Crohn's and Colitis, 17, pp. i650 - i651, http://dx.doi.org/10.1093/ecco-jcc/jjac190.0653
,2023, 'P663 Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn’s disease patients: results from the AURORA Study including ANZIBDC Cohort', Journal of Crohn's and Colitis, 17, pp. i793 - i794, http://dx.doi.org/10.1093/ecco-jcc/jjac190.0793
,2023, 'P753 Comparing long-term outcomes in inflammatory bowel disease patients between switch and non-switch cohorts: no differences in infliximab persistence or safety outcomes after 54 months', Journal of Crohn's and Colitis, 17, pp. i884 - i885, http://dx.doi.org/10.1093/ecco-jcc/jjac190.0883
,2023, '1029 WITHDRAWAL VERSUS CONTINUATION OF THIOPURINE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS (VIEWS): A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL', Gastroenterology, 164, pp. S - 221, http://dx.doi.org/10.1016/s0016-5085(23)01488-9
,2023, 'Su1782 QUALITY, SAFETY AND EQUITY OF CARE OUTCOMES FOR INFLAMMATORY BOWEL DISEASE PATIENTS AT FOUR AUSTRALIAN TERTIARY REFERRAL CENTRES USING THE CLOUD-BASED MANAGEMENT SYSTEM CROHN'S COLITIS CARE (CCCARE) : A REAL WORLD OBSERVATIONAL STUDY', Gastroenterology, 164, pp. S - 679, http://dx.doi.org/10.1016/s0016-5085(23)02580-5
,2022, 'Type 2 autoimmune pancreatitis associated with severe ulcerative colitis: Three case reports', World Journal of Clinical Cases, 10, pp. 8788 - 8796, http://dx.doi.org/10.12998/wjcc.v10.i24.8788
,2022, 'Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn's disease', World Journal of Gastroenterology, 28, pp. 2597 - 2608, http://dx.doi.org/10.3748/wjg.v28.i23.2597
,2022, 'Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial', The Lancet Gastroenterology and Hepatology, 7, pp. 141 - 151, http://dx.doi.org/10.1016/S2468-1253(21)00400-3
,2021, 'Lyophilised orally administered faecal microbiota transplantation for Active Ulcerative Colitis (LOTUS study)', JOURNAL OF CROHNS & COLITIS, 15, pp. S029 - S029, http://dx.doi.org/10.1093/ecco-jcc/jjab075.029
,2021, 'Australia IBD Microbiome (AIM) Study: Protocol for a multicentre longitudinal prospective cohort study', BMJ Open, 11, http://dx.doi.org/10.1136/bmjopen-2020-042493
,2021, 'Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study', Medical Journal of Australia, 214, pp. 128 - 133, http://dx.doi.org/10.5694/mja2.50824
,2021, 'The role of diet in the pathogenesis and management of inflammatory bowel disease: A review', Nutrients, 13, pp. 1 - 26, http://dx.doi.org/10.3390/nu13010135
,2021, '680 LYOPHILIZED ORALLY ADMINISTERED FECAL MICROBIOTA TRANSPLANTATION IN THE MANAGEMENT OF ULCERATIVE COLITIS (LOTUS STUDY) – RESULTS FROM THE INDUCTION PHASE OF A RANDOMIZED CONTROLLED TRIAL', Gastroenterology, 160, pp. S - 135, http://dx.doi.org/10.1016/s0016-5085(21)01074-x
,2021, 'SARS-CoV-2 vaccination in patients with inflammatory bowel disease.', GastroHep, 3, pp. 212 - 228, http://dx.doi.org/10.1002/ygh2.473
,2020, 'Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford', World Journal of Gastroenterology, 26, pp. 4428 - 4441, http://dx.doi.org/10.3748/WJG.V26.I30.4428
,2020, 'Myocarditis in Crohn's disease: A case report', European Heart Journal - Case Reports, 4, pp. 1 - 6, http://dx.doi.org/10.1093/ehjcr/ytaa120
,2020, 'Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty', Internal Medicine Journal, 50, pp. 798 - 804, http://dx.doi.org/10.1111/imj.14889
,2020, 'Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice', Gut, 69, pp. 801 - 810, http://dx.doi.org/10.1136/gutjnl-2019-320260
,2020, 'Level of UV Exposure, Skin Type, and Age Are More Important than Thiopurine Use for Keratinocyte Carcinoma Development in IBD Patients', Digestive Diseases and Sciences, 65, pp. 1172 - 1179, http://dx.doi.org/10.1007/s10620-019-05818-w
,2020, 'Effects of UVR exposure on the gut microbiota of mice and humans', Photochemical and Photobiological Sciences, 19, pp. 20 - 28, http://dx.doi.org/10.1039/c9pp00443b
,2019, 'Pericardial Mesothelioma in a 35-Year-Old Male With Ulcerative Colitis', Circulation. Cardiovascular imaging, 12, pp. e008659, http://dx.doi.org/10.1161/CIRCIMAGING.118.008659
,2019, 'Inflammatory bowel diseases: interrelationships between dietary vitamin D, exposure to UV radiation and the fecal microbiome', Expert Review of Gastroenterology and Hepatology, 13, pp. 1039 - 1048, http://dx.doi.org/10.1080/17474124.2019.1685874
,2019, 'Vitamin D metabolites are lower with active Crohn’s disease and spontaneously recover with development of remission', Therapeutic Advances in Gastroenterology, 12, http://dx.doi.org/10.1177/1756284819865144
,2018, 'High Dose Vitamin D supplementation alters faecal microbiome and predisposes mice to more severe colitis', Scientific Reports, 8, http://dx.doi.org/10.1038/s41598-018-29759-y
,2018, 'Letter: vedolizumab drug concentrations in neonates following intrauterine exposure', Alimentary Pharmacology and Therapeutics, 48, pp. 1328 - 1330, http://dx.doi.org/10.1111/apt.15027
,2018, 'Vitamin D C3-epimer levels are proportionally higher with oral vitamin D supplementation compared to ultraviolet irradiation of skin in mice but not humans.', The Journal of Steroid Biochemistry and Molecular Biology, 186, pp. 110 - 116, http://dx.doi.org/10.1016/j.jsbmb.2018.10.002
,2018, 'What is in our treasure chest? Australian pharmaceutical benefits scheme availability and criteria for prescribing biologics', Journal of Gastroenterology and Hepatology (Australia), 33, pp. 12 - 13, http://dx.doi.org/10.1111/jgh.14420
,2018, 'Ultraviolet irradiation of skin alters the faecal microbiome independently of vitamin D in mice', Nutrients, 10, http://dx.doi.org/10.3390/nu10081069
,2018, 'P120 Vitamin D deficiency in Crohn’s disease', Journal of Crohn's and Colitis, 12, pp. S152 - S153, http://dx.doi.org/10.1093/ecco-jcc/jjx180.247
,